Results 311 to 320 of about 1,501,016 (387)

Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data. [PDF]

J Crohns Colitis
Panés J, Dubinsky MC, Ishiguro Y, Shukla N, Dubcenco E, Remple V, Sharma D, Panaccione R.   +7 more
europepmc   +1 more source

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman, Ankita Narang, Ziad Al Bkhetan, Robyn L. Woods, Suzanne G. Orchard, Alice J. Owen, Michelle A. Fravel, Julia Gilmartin‐Thomas, Joanne Ryan, Peter D. Fransquet, Rory Wolfe, Chenglong Yu, John J. McNeil, Paul Lacaze, Michael E. Ernst   +14 more
wiley   +1 more source

Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.

JAMA Netw Open
Keating JA, Xu T, Graham MB, Ramesh M, Khanna S, Dixon J, Kates A, Haight K, Zhao J, Saddler C, Safdar N.   +10 more
europepmc   +1 more source

A systematic review and meta analysis of open label placebo effects in chronic musculoskeletal pain. [PDF]

Sci Rep
Borg F, Gedin F, Franzén E, Grooten WJA.   +3 more
europepmc   +1 more source

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis

Clinical Pharmacology &Therapeutics, EarlyView.
The objective of this modeling and simulation analysis was to determine an intravenous (IV) secukinumab dosing regimen with steady‐state exposure within the ranges of the approved subcutaneous (SC) regimens (300 and 150 mg every 4 weeks [q4w]) and to predict the efficacy and safety of this IV regimen for patients with psoriatic arthritis (PsA) or axial
Thomas Dumortier, Guillermo Valenzuela, Melvin Churchill, Jelena Mijatovic, Gerard Bruin, Luminita Pricop, Hanno Richards, Didier Renard, Atul Singhal, Anshu Marathe   +9 more
wiley   +1 more source

Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson's disease in China: a randomized clinical trial. [PDF]

BMC Complement Med Ther
Zhao Y, Li L, Huang D, Li W, Zhao Q, Liu H, Xiong R, Liu M, Gan J, Wu N, Liu Z, Chen X, Zhang S, Feng H, Lu J, Chen X, Zhang Y, Zhao X, Liu Z.   +18 more
europepmc   +1 more source

Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments

Clinical Pharmacology &Therapeutics, EarlyView.
Optimal dosing of oncological drugs is historically determined based on the “higher is better” paradigm. However, a paradigm shift in optimal dose selection has occurred in the development of new modalities, including molecularly targeted drugs, antibody drugs, and immunotherapies.
Hiroe Kitagaki, Kentaro Takeda, Kazuya Murai, Hideki Maeda   +3 more
wiley   +1 more source

Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.

JAMA Neurol
Jensen RH, Tassorelli C, Tepper SJ, Charles A, Goadsby PJ, Snoer AH, Sperling B, Krog Josiassen M, Borgen Linander C, Ettrup A, Boneva N.   +10 more
europepmc   +1 more source

Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis. [PDF]

Cardiooncology
Liu R, Fan C, Liu X, Li M, Zhang Y, Zhang M.   +5 more
europepmc   +1 more source

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study

Clinical Pharmacology &Therapeutics, EarlyView.
Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous) are being used. Unclear is whether LSD base and tartrate pharmacokinetics are equivalent.
Denis Arikci, Friederike Holze, Lorenz Mueller, Patrick Vizeli, Deborah Rudin, Dino Luethi, Cedric M. Hysek, Matthias E. Liechti   +7 more
wiley   +1 more source